IL17A and coronary artery disorder: Further analysis using KEGG revealed that the mechanism of action of BYXD in treating CHD involves the AGE-RAGE signaling pathway, TNF signaling pathway, HIF-1 signaling pathway, and IL-17 signaling pathway.